Follow Binaytara on FacebookFollow Binaytara on XFollow Binaytara on LinkedinFollow Binaytara on BlueskyFollow Binaytara on Instagram
Binaytara logo
  • About Us
  • CME Conferences
  • Funding Opportunities
  • Projects
  • Get Involved
  • News
Saturday, October 3, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

All Articles
Cancer Education
  • Resources for Cancer Patients
Perspectives
Clinical Breakthroughs & Research
Health Equity
About Us
  • Contributors
  • Ethics and Disclosure Policy
  • Editorial Standards & Corrections Policy
Article Submission
The Cancer News>Cancer Education>New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

Browse by Topics

Cancer EducationPerspectivesHealth EquityHealth PolicyResources for Cancer PatientsResearch
More from Cancer Education
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors

Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors

September 28, 2026

Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show

Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show

September 28, 2026

HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer

HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer

September 24, 2026

Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop

Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop

September 21, 2026

Novel Agents and MRD-Guided Therapy Are Reshaping Frontline Lymphoma Care

Novel Agents and MRD-Guided Therapy Are Reshaping Frontline Lymphoma Care

September 21, 2026

Advances in the Management of Lung Cancer in 2025 and 2026

Advances in the Management of Lung Cancer in 2025 and 2026

Leptomeningeal Disease Is Becoming More Common, and Also More Treatable

Leptomeningeal Disease Is Becoming More Common, and Also More Treatable

Share Article

Get the Quick Bites delivered to your inbox daily

Binaytara logo

19-years of advocating, educating and innovating to improve Cancer Care.

Useful Links

  • News and Stories
  • OncoBlast
  • Careers
  • Donate

US Address

  • Binaytara
  • 3380 146th Pl SE, Suite 340
  • Bellevue, WA 98007 USA

Nepal Address

  • Binaytara Country Office
  • Kadam Chowk
  • Janakpur, NEPAL
  • _______
  • Binaytara Cancer Center
  • Janakpur, NEPAL

Legal

  • Privacy Policy

Binaytara is a 501(c)(3) not-for-profit organization. Our EIN number. is 26-1603676. © 2026, Binaytara. All rights reserved

Follow Binaytara on FacebookFollow Binaytara on BlueskyFollow Binaytara on LinkedinFollow Binaytara on YoutubeFollow Binaytara on TwitterFollow Binaytara on Instagram